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Aims Over the last decades, the profile of chronic coronary syndrome has changed substantially. We aimed to determine
characteristics and management of patients with chronic coronary syndrome in the contemporary era, as well as
outcomes and their determinants.
...................................................................................................................................................................................................
Methods
and results
Data from 32 703 patients (45 countries) with chronic coronary syndrome enrolled in the prospective observa-
tional CLARIFY registry (November 2009 to June 2010) with a 5-year follow-up, were analysed. The primary out-
come [cardiovascular death or non-fatal myocardial infarction (MI)] 5-year rate was 8.0% [95% confidence interval
(CI) 7.7–8.3] overall [male 8.1% (7.8–8.5); female 7.6% (7.0–8.3)]. A cox proportional hazards model showed that
the main independent predictors of the primary outcome were prior hospitalization for heart failure, current smok-
ing, atrial fibrillation, living in Central/South America, prior MI, prior stroke, diabetes, current angina, and peripheral
artery disease. There was an interaction between angina and prior MI (P= 0.0016); among patients with prior MI,
angina was associated with a higher primary event rate [11.8% (95% CI 10.9–12.9) vs. 8.2% (95% CI 7.8–8.7) in
patients with no angina, P< 0.001], whereas among patients without prior MI, event rates were similar for patients
with [6.3% (95% CI 5.4–7.3)] or without angina [6.4% (95% CI 5.9–7.0)], P> 0.99. Prescription rates of evidence-
based secondary prevention therapies were high.
...................................................................................................................................................................................................
Conclusion This description of the spectrum of chronic coronary syndrome patients shows that, despite high rates of prescrip-
tion of evidence-based therapies, patients with both angina and prior MI are an easily identifiable high-risk group
who may deserve intensive treatment.
...................................................................................................................................................................................................
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Introduction
Over the last decades, the management and prognosis of chronic
coronary syndrome has improved considerably and consequently
cardiovascular mortality has declined steadily.1 Outcomes following
acute myocardial infarction (MI) have improved following the advent
of reperfusion therapy with thrombolysis or primary angioplasty2 and
widespread implementation of evidence-based secondary prevention
medications,3 including aspirin and other antiplatelet agents,4,5 sta-
tins,6 beta-blockers,7 and renin–angiotensin antagonists.8,9 In addition,
the profile of these patients has changed with the use of coronary
revascularization, particularly percutaneous coronary intervention
(PCI) as well as the improved survival of patients experiencing an
acute coronary syndrome (ACS). Whereas in the past, patients with
chronic coronary syndrome were largely defined as patients with
‘stable angina’,10–12 today these patients are a heterogeneous group
encompassing patients with or without symptoms of angina pectoris,
with or without a history of coronary revascularization, and with or
without a history of prior and often remote ACS.13,14 While there is
a wealth of information regarding the acute and short-term out-
comes of ACS patients, less is known regarding the contemporary
characteristics, management, and long-term prognosis of the broad
chronic coronary syndrome population.
The CLARIFY registry (ProspeCtive observational LongitudinAl
RegIstry oF patients with stable coronary arterY disease; ISRCTN
43070564) was established to provide information regarding the pro-
file and prognosis of chronic coronary syndrome in clinical practice,
across a broad range of geographic regions.
The aim of the present study was to describe the characteristics
and management of chronic coronary syndrome patients and to es-
tablish the determinants of their long-term prognosis with a focus on
assessing the relative importance of angina and a history of MI.
Methods
Study design and participants
The rationale, design, and preliminary baseline characteristics of the
CLARIFY registry have been described in detail previously.13,15,16 Briefly,
between 26 November 2009 and 30 June 2010, 32 703 chronic coronary
syndrome patients were enrolled in 45 countries (Supplementary mater-
ial online, Table S1), encompassing patients from high/middle/low-income
countries organized in six geographical areas: Western/Central Europe,
Eastern Europe, Middle East, Asia, Central/South America, and some
Commonwealth countries (Australia/Canada/South Africa/UK).
Patients were eligible for enrolment if they fulfilled >_1 of the following
criteria (not mutually exclusive): documented MI for more than 3 months
before enrolment, coronary artery bypass grafting (CABG) or PCI for
more than 3 months before enrolment, chest pain with proven myocar-
dial ischaemia, or previous coronary angiography showing at least one
coronary stenosis of more than 50%. Exclusion criteria were
hospitalization for cardiovascular disease within the previous 3 months,
planned revascularization, and conditions interfering with 5-year follow-
up, including severe heart failure (HF). Severe HF was left to the investiga-
tor opinion without providing an left ventricular ejection fraction (LVEF)
threshold (which would not take into account HF with preserved ejec-
tion fraction), or New York Heart Association class (which can transient-
ly improve).
Patients were enrolled over a brief period to minimize the risk of se-
lection bias and were followed-up yearly for up to 5 years. Medical care
was at the discretion of each physician. Outcomes were not adjudicated,
but investigators were provided with definitions for each outcome in
case report forms. Yearly, 1% of sites were randomly selected for onsite
audit of 100% of the data.
CLARIFY was conducted in accordance with the Declaration of
Helsinki and local ethical approval was obtained in each country. All
patients gave informed consent.
Outcomes
The primary outcome was the composite of cardiovascular death or
non-fatal MI. Secondary outcomes were cardiovascular death, non-
cardiovascular death, all-cause death, the triple composite of cardiovascu-
lar death, non-fatal MI or non-fatal stroke, fatal MI, fatal stroke, non-fatal
MI, non-fatal stroke, hospitalization for HF, coronary angiography, PCI,
and CABG.
Statistical analyses
Baseline characteristics were analysed according to history of MI and/or
angina at baseline, using mean (±standard deviation) for continuous varia-
bles, and counts (and percentages) for categorical variables. Continuous
and categorical variables were compared across groups using Student’s
and v2 tests, respectively. Baseline characteristics were also analysed
across geographical areas and compared using analyses of variance and v2
tests, where appropriate.
Five-year rates with 95% confidence intervals (CIs) were estimated by
Kaplan–Meier method in the total population, according to gender as
well as in clinical subgroups (according to history of prior MI and/or an-
gina status at baseline, independently or combined). Comparisons across
subgroups were performed using the log-rank tests.
To determine the main predictors of cardiovascular death or non-fatal
MI, an univariate and a multivariable analysis without selection (cause-spe-
cific Cox proportional hazards model) determined hazard ratios (HRs)
and 95% CI, including as potential predictors: (i) cardiovascular risk fac-
tors [age, sex, diabetes, smoking status (current/former/never), and
treated hypertension]; (ii) medical history [prior MI, PCI, CABG, or hospi-
talization for HF, asthma/chronic obstructive pulmonary disease, atrial fib-
rillation/flutter, prior stroke, cerebrovascular disease, peripheral artery
disease (PAD)]; (iii) clinical parameters [current angina, blood pressure
(BP) <140/90 mmHg]; (iv) treatments (aspirin, statins); and (v) geograph-
ical zones. Only factors showing a P-value of significance lower than 0.2 in
univariate models were introduced in the multivariable model. The inter-
action between prior MI and angina status was assessed using unadjusted
and adjusted Cox models. The effect of this interaction to the predictors
of the primary outcome was assessed by adding the interaction between
prior MI and angina in the previous multivariable model.
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Analyses were performed using SAS software version 9.3 (SAS
Institute Inc., Cary, NC, USA).
Role of the funding source
The CLARIFY registry is supported by Servier. The sponsor had no role
in the study design, data analysis and interpretation, or decision to submit
the manuscript for publication, but assisted with the set-up, data collec-
tion, and management of the study in each country. The corresponding
author had full access to all data and had the final responsibility for the de-
cision to submit for publication.
Results
A total of 33 299 patients were screened. Five hundred and ninety-
six withdrew consent and/or did not meet the inclusion criteria and/
or did not have baseline information available, leaving a study popula-
tion of 32 703 participants with planned follow-up up to 5 years (me-
dian follow-up 5.0 years; interquartile range 4.8–5.1) (Supplementary
material online, Figure S1).
Baseline characteristics of the entire CLARIFY population were
previously described.13 Briefly, patients had a mean age of
64.2± 10.5 years, 22.4% were women, 71.0% had a history of hyper-
tension. As expected from the inclusion criteria, prior MI (59.9%) and
prior revascularization (PCI = 58.6%; CABG = 23.6%) were common.
A minority of the patients had angina (22.1%), HF symptoms
(15.1%), or HF symptoms and LVEF >_50% (10.2%). The prevalence
of HF symptoms with LVEF >_50% was higher in female (13.8%) than
in male (9.0%), P< 0.001. Rates for use of secondary prevention
therapies, such as antiplatelet agents, statins, beta-blockers, and
renin–angiotensin system (RAS) inhibitors (angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers) were: 95.2%,
82.9%, 75.3%, and 76.3%, respectively (Supplementary material on-
line, Table S2).
Compared with patients without prior MI, patients with a history
of prior MI were younger, more often males and current or former
smokers, had a lower prevalence of treated hypertension, a higher
prevalence of family history of premature coronary disease, and his-
tory of PCI. They had more symptoms of angina or HF, and lower
LVEF. They were more likely to receive guideline-recommended sec-
ondary prevention therapies (Table 1).
Compared with patients without angina, patients with angina were
younger, more frequently females, had a higher prevalence of cardio-
vascular risk factors and history of hospitalization for HF, lower LVEF,
higher rates of prior MI, lower extremity artery disease or cerebro-
vascular disease, and fewer prior coronary revascularization proce-
dures. The use of medication was similar for single antiplatelet
therapy and statins, but higher for antianginal drugs and RAS inhibi-
tors in the angina subgroup. Rate of non-current smoking was lower
in patients with angina (Table 1).
Baseline characteristics according to combined prior MI and angina
status at study entry are reported in Supplementary material online,
Table S3.
Across geographical regions, substantial variations in clinical pro-
files were observed (Supplementary material online, Table S4).
Patients enrolled in Eastern Europe were the youngest and had the
lowest prevalence of diabetes, but the highest prevalence of treated
hypertension, current smoking, prior MI, prior hospitalization for HF,
current angina, or HF symptoms, and the highest rate of RAS inhibi-
tors use. In participating centres from the Middle East, patients had
the lowest rate of current HF symptoms, the highest body mass index
and the highest prevalence of diabetes. They had the lowest rate of
lower extremity artery disease and family history of coronary disease.
They had also the lowest LVEF. The overall use of secondary preven-
tion therapy was the highest. Centres from Asia had the lowest
prevalence of prior MI, the highest rate of prior PCI, but the lowest
rate of CABG, the highest rate of stroke, and the smallest body mass
index, and the lowest rate of use of statins and RAS inhibitors.
Central/South America enrolled the highest proportion of females
and the lowest rate of current smokers, prior stroke, or angina
patients, but the highest rate of BP <140/90 mmHg. Commonwealth
countries were characterized by the oldest population, with the high-
est rate of family history of premature coronary disease, prior transi-
ent ischaemic attack, or CABG, and the lowest rate of use of single
antiplatelet therapy and beta-blockers. Western/Central Europe had
the highest proportion of males and the highest prevalence of lower
extremity artery disease.
In the CLARIFY cohort, the 5-year crude rate of cardiovascular
death or non-fatal MI was 8.0% (95% CI 7.7–8.3), the rate of cardio-
vascular death, non-fatal MI, or non-fatal stroke was 9.5% (95% CI
9.2–9.9), and the cardiovascular death rate was 5.5% (95% CI 5.3–
5.8). Approximately 20% of cardiovascular deaths were due to MI
and nearly 10% to stroke. All-cause death was 8.5% (95% CI 8.2–8.9)
and non-cardiovascular death was 3.2% (95% CI 3.0–3.4).
Approximately 15% of patients required coronary angiography dur-
ing follow-up, of which half resulted in PCI and close to 10% in CABG
(Table 2).
The primary event rate was 7.6% (95% CI 7.0–8.3) for female and
8.1% (95% CI 7.8–8.5) for male. Overall, 5-year event rates were
similar regardless of the gender, but female were significantly less
revascularized than male: 6.6% (95% CI 6.1–7.3) vs. 7.7% (95% CI
7.4–8.1), respectively for PCI (Supplementary material online, Table
S5).
Patients with prior MI experienced worse outcomes than patients
without prior MI. Rates of cardiovascular death or non-fatal MI were
9.1% (95% CI 8.7–9.5) and 6.4% (95% CI 6.0–6.9), respectively
(P< 0.001). They also had a significantly higher rate of cardiovascular
death and of the triple composite endpoint. Compared with patients
without angina, patients with angina had a higher rate of cardiovascu-
lar death or non-fatal MI with rates of 9.8% (95% CI 9.1–10.5) and
7.5% (95% CI 7.1–7.8), respectively (P< 0.001). They also had higher
rates of cardiovascular death and triple composite endpoint
(Table 2).
There was an interaction between angina and history of MI regard-
ing the primary endpoint (P= 0.0016 with multivariable analysis), and
the main secondary endpoints. This interaction was not time-
dependent (Supplementary material online, Table S6). After stratifica-
tion into four mutually exclusive subgroups according to the com-
bined presence of angina at baseline and history of prior MI, angina
was associated with a worse prognosis only in patients with a history
of prior MI (Take home figure). In the subset of patients with prior MI,
the 5-year rate of cardiovascular death or non-fatal MI was 11.8%
(95% CI 10.9–12.9) for angina patients vs. 8.2% (95% CI 7.8–8.7) for
non-angina patients (P< 0.001). In the subset of patients without
prior MI, this rate was 6.3% (95% CI 5.4–7.3) for angina patients vs.
Long-term outcomes of chronic coronary syndrome worldwide 3
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Table 1 Baseline characteristics according to history of MI status or according to current angina status
Prior MI
(N5 19 595)
No prior MI
(N5 13 100)
P-value Angina
at baseline
(N5 7212)
No angina
at baseline
(N525 479)
P-value
Risk factors and lifestyle
Age (years) 63.1 ± 10.7 (19 587) 65.8 ± 9.4 (13 093) <0.001 63.04 ± 10.2 (7208) 64.5 ± 10.5 (25 468) <0.001
Male 80.8% (15 825/19 589) 72.8% (9534/13 096) <0.001 71.5% (5154/7210) 79.3% (20 203/25 471) <0.001
Treated hypertension 69.1% (13 538/19 591) 73.8% (9669/13 099) <0.001 78.5% (5658/7212) 68.9% (17 549/25 477) <0.001
Diabetes 28.6% (5601/19 589) 29.7% (3895/13 099) 0.026 28.6% (2062/7212) 29.2% (7433/25 474) 0.332
Dyslipidaemia 75.9% (14 877/19 591) 73.5% (9622/13 099) <0.001 78.8% (5683/7212) 73.9% (18 815/25 476) <0.001
Smoking status
Current 14.3% (2805/19 594) 9.7% (1272/13 099) <0.001 15.0% (1078/7212) 11.8% (2999/25 479) <0.001
Former 49.2% (9641/19 594) 41.7% (5463/13 099) 41.4% (2982/7212) 47.6% (12 121/25 479)
Never 36.5% (7148/19 594) 48.6% (6364/13 099) 43.7% (3152/7212) 40.7% (10 359/25 479)
Family history of premature
coronary disease
29.1% (5704/19 590) 27.7% (3622/13 098) 0.004 35.4% (2552/7212) 26.6% (6773/25 476) <0.001
No physical activity 15.5% (3040/19 588) 17.2% (2246/13 095) <0.001 14.6% (1056/7211) 16.6% (4230/25 472) <0.001
Medical history
Myocardial infarction 100.0% (19 595/19 595) 0.0% (0/13 100) NA 62.5% (4507/7211) 59.2% (15 084/25 478) <0.001
PCI 60.3% (11 812/19 594) 56.1% (7348/13 099) <0.001 41.9% (3018/7211) 63.4% (16 140/25 477) <0.001
CABG 21.5% (4217/19 592) 26.6% (3484/13 099) <0.001 19.3% (1392/7210) 24.8% (6308/25 476) <0.001
Cerebrovascular disease
Stroke 4.1% (801/19 593) 3.9% (513/13 100) 0.437 5.3% (383/7211) 3.7% (931/25 477) <0.001
Transient ischemic attack 2.8% (541/19 592) 3.5% (460/13 100) <0.001 4.8% (345/7211) 2.6% (656/25 476) <0.001
Carotid disease 6.7% (1312/19 594) 8.9% (1162/13 100) <0.001 9.6% (694/7211) 7.0% (1779/25 478) <0.001
Peripheral arterial disease
Lower extremity artery disease 9.7% (1900/19 590) 10.2% (1338/13 099) 0.126 13.0% (938/7212) 9.0% (2301/25 475) <0.001
Aortic abdominal aneurysm 1.6% (311/19 592) 1.5% (193/13 099) 0.412 1.2% (89/7211) 1.6% (415/25 475) 0.016
Hospitalization for HF 5.5% (1085/19 593) 3.4% (445/13 100) <0.001 7.5% (537/7211) 3.9% (993/25 477) <0.001
Atrial fibrillation/flutter 6.4% (1255/19 593) 8.1% (1057/13 100) <0.001 7.4% (531/7211) 7.0% (1781/25 477) 0.275
Asthma/COPD 7.3% (1437/19 593) 7.5% (982/13 100) 0.584 9.1% (654/7211) 6.9% (1765/25 477) <0.001
Clinical examination
Angina symptoms 23.0% (4507/19 591) 20.6% (2704/13 098) <0.001 100.0% (7212/7212) 0.0% (0/25 479) NA
HF symptoms 18.5% (3628/19 590) 10.0% (1296/13 098) <0.001 40.4% (2912/7211) 7.9% (2013/25 478) <0.001
Systolic BP (mmHg) 130.1 ± 16.6 (19 576) 132.5 ± 16.6 (13 094) <0.001 133.5 ± 17.5 (7211) 130.3 ± 16.4 (25 455) <0.001
Diastolic BP(mmHg) 77.3 ± 10.1 (19 576) 77.3 ± 9.8 (13 094) 0.940 79.5 ± 10.7 (7211) 76.6 ± 9.7 (25 455) <0.001
Pulse (b.p.m.) 68.3 ± 10.5 (19 577) 68.1 ± 10.7 (13 091) 0.074 69.8 ± 10.9 (7212) 67.8 ± 10.5 (25 452) <0.001
Body mass index (kg/m2) 28.1 ± 4.7 (19 573) 27.6 ± 4.5 (13 081) <0.001 28.6 ± 4.8 (7202) 27.7 ± 4.5 (25 448) <0.001
Paraclinical parameters
LVEF (%) 53.7 ± 11.2 (13 963) 60.0 ± 9.6 (8554) <0.001 55.3 ± 10.4 (5422) 56.3 ± 11.3 (17 091) <0.001
Coronary arteries involveda
Left main 7.9% (1555/19 585) 9.9% (1293/13 097) <0.001 8.7% (624/7210) 8.7% (2224/25 469) 0.837
LAD 55.9% (10 947/19 585) 62.0% (8113/13 097) <0.001 44.5% (3211/7210) 62.2% (15 848/25 469) <0.001
Cx 34.9% (6834/19 585) 37.9% (4959/13 097) <0.001 29.5% (2128/7210) 37.9% (9663/25 469) <0.001
RCA 44.5% (8711/19 585) 42.2% (5520/13 097) <0.001 36.8% (2655/7210) 45.4% (11 574/25 469) <0.001
Bypass graft 7.7% (1510/19 585) 8.6% (1120/13 097) 0.006 7.5% (543/7210) 8.2% (2087/25 469) 0.068
No significant stenosis 3.1% (608/19 585) 3.4% (449/13 097) 0.105 3.9% (284/7210) 3.0% (773/25 469) <0.001
Angiography not done <12 months 16.5% (3223/19 585) 11.8% (1540/13 097) <0.001 31.7% (2282/7210) 9.7% (2481/25 469) <0.001
Baseline medications
Aspirin 89.1% (17 446/19 587) 85.8% (11 236/13 097) <0.001 89.1% (6423/7212) 87.4% (22 258/25 471) <0.001
Any antiplatelet therapy 95.8% (18 761/19 590) 94.2% (12 342/13 097) <0.001 95.0% (6854/7212) 95.2% (24 248/25 474) 0.598
Dual antiplatelet therapy 28.8% (5647/19 590) 26.7% (3496/13 097) <0.001 23.8% (1717/7212) 29.2% (7425/25 474) <0.001
Oral anticoagulants 8.1% (1590/19 573) 8.2% (1078/13 089) 0.716 7.9% (569/7208) 8.3% (2101/25 453) 0.324
Lipid lowering agents 93.6% (18 333/19 590) 90.5% (11 853/13 097) <0.001 91.3% (6584/7212) 92.7% (23 601/25 474) <0.001
Continued
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Table 1 Continued
Prior MI
(N5 19 595)
No prior MI
(N5 13 100)
P-value Angina
at baseline
(N5 7212)
No angina
at baseline
(N525 479)
P-value
Statins 84.7% (16 583/19 590) 80.3% (10 512/13 097) <0.001 82.9% (5978/7212) 82.9% (21 115/25 474) 0.998
Beta-blockers 79.0% (15 471/19 591) 69.8% (9136/13 096) <0.001 78.8% (5681/7212) 74.3% (18 924/25 474) <0.001
Calcium antagonists 23.0% (4504/19 588) 33.6% (4405/13 095) <0.001 31.8% (2296/7212) 26.0% (6613/25 470) <0.001
Ivabradine 10.3% (2015/19 588) 9.2% (1203/13 097) 0.001 21.3% (1533/7211) 6.6% (1685/25 473) <0.001
Nitrates or other antianginal drugsb 30.6% (5990/19 581) 30.0% (3930/13 096) 0.262 55.9% (4030/7209) 23.1% (5887/25 467) <0.001
ACE-inhibitors or ARB 79.6% (15 588/19 584) 71.3% (9333/13 095) <0.001 80.3% (5794/7212) 75.1% (19 127/25 473) <0.001
Diuretics 30.5% (5962/19 585) 27.6% (3621/13 097) <0.001 36.2% (2609/7212) 27.4% (6975/25 469) <0.001
NSAID 4.8% (929/19 581) 5.2% (684/13 097) 0.051 6.4% (459/7211) 4.5% (1155/25 465) <0.001
Amiodarone/dronedarone 3.2% (623/19 581) 2.6% (338/13 096) 0.002 3.7% (265/7211) 2.7% (697/25 465) <0.001
Insulin in diabetics 21.6% (1209/5599) 21.5% (838/3894) 0.932 23.3% (481/2062) 21.1% (1566/7432) 0.932
Oral diabetic drugs in diabetics 68.4% (3834/5599) 70.4% (2742/3894) 0.044 68.1% (1404/2062) 69.6% (5174/7432) <0.001
Groups according to history of prior MI or angina are non-mutually exclusive.
Data are expressed in mean ± standard deviation for continuous variables or % for categorical variables. For categorical data, the number of concerned patients/number of avail-
able data are indicated in brackets. For continuous data, the number of available data are indicated in brackets.
Categorical and continuous variables were compared across groups by v2 and Student’s t-test, respectively. Continuous variables are presented by mean or median according
to the distribution.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blockers; BP, blood pressure; CABG, coronary artery bypass graft; COPD, chronic obstructive coronary dis-
ease; HF, heart failure; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NSAID, non-steroidal
anti-inflammatory drugs; PCI, percutaneous coronary intervention; RCA, right coronary artery; SD, standard deviation.
aWith stenosis >50% at coronary angiography or having required revascularization in the past.
bOther antiaginal drugs: molsidomine, nicorandil, ranolazine, or trimetazidine.
....................................................................................................................................................................................................................
Table 2 Five-year event rates (95% CI) in the entire cohort and according to history of prior MI or the presence of an-
ginal symptoms at baseline
All CLARIFY
(N532 703)
Prior MI
(N5 19 595)
No prior MI
(N5 13 100)
P-value Angina
(N5 7212)
No angina
(N5 25 479)
P-value
Primary outcome
CV death or Non-fatal MI 8.0 (7.7–8.3) 9.1 (8.7–9.5) 6.4 (6.0–6.9) <0.001 9.8 (9.1–10.5) 7.5 (7.1–7.8) <0.001
Secondary outcomes
CV death 5.5 (5.3–5.8) 6.3 (5.9–6.6) 4.4 (4.0–4.8) <0.001 6.3 (5.7–6.9) 5.3 (5.0–5.6) 0.001
Non-CV death 3.2 (3.0–3.4) 3.3 (3.1–3.6) 3.0 (2.7–3.3) 0.096 3.0 (2.6–3.5) 3.3 (3.0–3.5) 0.295
All-cause death 8.5 (8.2–8.9) 9.4 (9.0–9.8) 7.3 (6.8–7.8) <0.001 9.1 (8.4–9.8) 8.4 (8.0–8.8) 0.050
CV death non-fatal MI or
non-fatal stroke
9.5 (9.2–9.9) 10.7 (10.3–11.2) 7.7 (7.2–8.2) <0.001 11.6 (10.8–12.4) 8.9 (8.5–9.3) <0.001
Fatal MI 1.1 (1.0–1.2) 1.4 (1.3–1.6) 0.7 (0.5–0.8) <0.001 1.5 (1.2–1.8) 1.0 (0.9–1.2) 0.001
Fatal stroke 0.6 (0.5–0.7) 0.7 (0.6–0.8) 0.5 (0.4–0.6) 0.034 0.9 (0.7–1.2) 0.5 (0.4–0.6) <0.001
Non-fatal MI 2.8 (2.6–3.0) 3.2 (2.9–3.5) 2.2 (1.9–2.5) <0.001 3.9 (3.5–4.4) 2.5 (2.3–2.7) <0.001
Non-fatal stroke 1.9 (1.7–2.0) 2.0 (1.8–2.3) 1.6 (1.4–1.9) 0.006 2.3 (1.9–2.7) 1.7 (1.6–1.9) 0.006
Hospitalization for heart failure 5.4 (5.2–5.7) 6.4 (6.1–6.8) 3.9 (3.6–4.3) <0.001 10.7 (10.0–11.5) 3.9 (3.6–4.1) <0.001
Coronary angiography 15.0 (14.6–15.4) 14.2 (13.7–14.8) 16.1 (15.4–16.8) <0.001 19.7 (18.7–20.7) 13.6 (13.2–14.1) <0.001
PCI 7.5 (7.2–7.8) 7.1 (6.8–7.5) 7.9 (7.5–8.5) 0.006 9.6 (8.9–10.3) 6.8 (6.5–7.2) <0.001
CABG 1.5 (1.4–1.7) 1.6 (1.4–1.8) 1.4 (1.2–1.7) 0.345 2.5 (2.2–2.9) 1.2 (1.1–1.4) <0.001
Groups according to history of prior MI or angina are non-mutually exclusive.
All risks are described as Kaplan–Meier estimates with their 95% CI. P-values for group comparisons were estimated by log-ranks tests.
CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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..6.4% (95% CI 5.9–7.0) for patients without angina (P> 0.99). Similar
results were found for most secondary outcomes (Table 3).
There were substantial variations in crude event rates across geo-
graphical zones. Asia had the lowest rate of primary outcome and the
lowest mortality (all-cause, cardiovascular, and non-cardiovascular).
Conversely, Central/South America had the highest rate of primary
outcome and the highest mortality, driven by the highest cardiovas-
cular death (Supplementary material online, Table S7).
Multivariable analysis identified the main independent predictors
of the primary composite outcome of cardiovascular death or non-
fatal MI (Figure 1) as history of hospitalization for HF (HR = 2.13; 95%
CI 1.87–2.42), current smoking (HR = 1.74; 95% CI 1.51–1.99), atrial
fibrillation/flutter (HR = 1.61; 95% CI 1.42–1.82), living in Central/
South America (HR = 1.61; 95% CI 1.38–1.88), prior MI (HR = 1.50;
95% CI 1.37–1.65), prior stroke (HR = 1.45; 95% CI 1.20–1.76), dia-
betes (HR = 1.40; 95% CI 1.28–1.53), current angina (HR = 1.30; 95%
CI 1.18–1.45), PAD (HR = 1.29; 95% CI 1.15–1.45), and former
smoker (HR = 1.29; 95% CI 1.17–1.42). Age was also an independent
predictor (HR = 1.04; 95% CI 1.03–1.04 for each 1-year increase). A
lower risk of cardiovascular death or non-fatal MI was independently
predicted by prior PCI (HR = 0.85; 95% CI 0.78–0.93) and BP <140/
90 mmHg (HR = 0.90; 95% CI 0.83–0.99). Gender was not an inde-
pendent predictor of cardiovascular death or non-fatal MI
(HR = 0.95; 95% CI 0.85–1.06, for female) as illustrated in Figure 1.
Univariate/multivariable analyses are reported in Supplementary ma-
terial online, Table S8. After adjustment with interaction between
prior MI and angina, the effect of these predictors was similar
(Supplementary material online, Figure S2).
Discussion
This large, international, observational, cohort of chronic coronary
syndrome patients provides several important observations with dir-
ect clinical implications.
First, since prior registries, such as Euro Heart Survey on stable an-
gina12 and REACH17,18 were started, the clinical characteristics of
patients with chronic coronary syndrome have changed. Compared
with the Euro Heart Survey on stable angina (enrolment 2002), and
with the REACH registry (enrolment 2003–2004), more patients in
CLARIFY were well treated in terms of exposure to secondary pre-
vention therapies, regardless of the clinical profile or geographical
area of enrolment. Moreover, patients in CLARIFY had more diverse
clinical profiles than in the Euro Heart Survey, which was focused ex-
clusively on patients with angina and without revascularization, and
than in the REACH registry, which enrolled patients at risk for or
with established atherothrombosis, including chronic coronary syn-
drome but which did not encompass the full spectrum of this syn-
drome. For example, REACH did not enroll patients with
documented coronary disease but without prior MI or PCI. This ob-
servation highlights the changing picture of chronic coronary artery
disease, a population which used to be defined largely via its angina
...................................................... ......................................................
....................................................................................................................................................................................................................
Table 3 Five-year outcomes according to combined history of prior MI and angina status
Prior MIa (N5 19 595) P-value No prior MIb (N5 13 100) P-value
Angina
(N5 4507)
No angina
(N5 15 084)
Angina
(N52704)
No angina
(N510 394)
5-year event
rate % (95% CI)
5-year event
rate % (95% CI)
5-year event
rate % (95% CI)
5-year event
rate % (95% CI)
Primary outcome
CV death or non-fatal MI 11.8 (10.9–12.9) 8.2 (7.8–8.7) <0.001 6.3 (5.4–7.3) 6.4 (5.9–7.0) >0.99
Secondary outcomes
Cardiovascular death 7.7 (7.0–8.6) 5.8 (5.4–6.2) <0.001 3.7 (3.1–4.6) 4.6 (4.2–5.1) 0.111
Non-CV death 3.3 (2.8–3.9) 3.3 (3.0–3.7) >0.99 2.5 (1.9–3.2) 3.1 (2.8–3.5) 0.069
All-cause death 10.8 (9.9–11.8) 8.9 (8.5–9.5) <0.001 6.1 (5.2–7.1) 7.6 (7.1–8.2) 0.017
CV death non-fatal MI or non-fatal stroke 13.7 (12.7–14.8) 9.8 (9.3–10.3) <0.001 8.0 (7.0–9.1) 7.6 (7.1–8.2) 0.448
Fatal MI 2.0 (1.6–2.5) 1.2 (1.1–1.5) <0.001 0.6 (0.4–1.0) 0.7 (0.5–0.9) 0.939
Fatal stroke 1.2 (0.9–1.6) 0.5 (0.4–0.7) <0.001 0.5 (0.3–0.8) 0.5 (0.4–0.7) 0.860
Non-fatal MI 4.6 (4.0–5.3) 2.7 (2.5–3.0) <0.001 2.8 (2.2–3.5) 2.0 (1.8–2.4) 0.034
Non-fatal stroke 2.5 (2.0–3.0) 1.9 (1.7–2.1) 0.019 1.9 (1.4–2.5) 1.5 (1.3–1.8) 0.189
Hospitalization for heart failure 13.0 (12.0–14.1) 4.4 (4.0–4.7) <0.001 6.8 (5.9–7.9) 3.1 (2.8–3.5) <0.001
Coronary angiography 19.0 (17.8–20.3) 12.8 (12.2–13.4) <0.001 20.7 (19.2–22.4) 14.9 (14.2–15.7) <0.001
PCI 9.2 (8.3–10.1) 6.5 (6.1–7.0) <0.001 10.2 (9.1–11.5) 7.3 (6.8–7.9) <0.001
CABG 2.5 (2.1–3.1) 1.3 (1.1–1.5) <0.001 2.5 (1.9–3.2) 1.2 (0.9–1.4) <0.001
Groups according to history of prior MI or angina are mutually exclusive.
aAmong the subset with prior MI angina status was missing for four patients.
bAmong the subset without prior MI angina status was missing for two patients.
All risks are described as Kaplan–Meier estimates with their 95% CI. P-values for group comparisons were estimated by log-rank tests.
CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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..symptoms, but which now covers a broad spectrum of clinical pre-
sentations, and prior medical history.
Second, in this cohort without severe HF, major cardiovascular
event rates were overall relatively low compared with previous regis-
tries,12,18 but encompassed substantial variation across geographic
zones. This may be related to secular trends in cardiovascular disease
but also to different selection criteria resulting in enrolment of a lower
risk population. In the CORONOR registry (enrolment 2010–2011),
which recruited an older population (mean age 66.9 ± 11.6 years), half
of deaths were non-cardiovascular and the rate of cardiovascular
death was slightly higher (1.3 per 100 patient-years) than in the pre-
sent study.19 Compared with contemporary randomized clinical trials
(RCTs), CLARIFY patients were overall at lower risk than those from
COMPASS20 (who required coronary artery disease enrichment cri-
teria to be enrolled), from FOURIER21 (with a higher prevalence of
prior MI) or from CANTOS22 (where all patients had a prior MI).
Third, major predictors of cardiovascular death or non-fatal MI
were a history of hospitalization for HF and other comorbidities,
such as atrial fibrillation or PAD, suggesting that these comorbidities
must not be considered as incidental in chronic coronary syndrome
patients and need to be more carefully targeted and treated.
Conventional cardiovascular risk factors were also predictors of
poor outcomes, highlighting that prevention and treatment of these
factors remains a major goal.
Fourth, the profile of women and men with chronic coronary syn-
drome differ substantially15 with a higher rate of HF with preserved
LVEF for women. However, gender was not an independent predict-
or of the primary outcome and 5-year event rates were overall simi-
lar regardless of the gender, other than a lower incidence of
revascularization in women. These results highlight the need of fur-
ther analyses to better understand gender determinants of outcome.
Fifth, history of prior MI and angina symptoms were both major
determinants of adverse cardiovascular outcomes, with a significant
statistical interaction. These results complement the previous findings
where angina was shown to be prognostically important, while silent
ischaemia without angina was not associated with a worse prognosis
at 1 year.14
While a history of prior MI was a determinant of poor prognosis
regardless of angina symptoms, angina had different implications de-
pending on the patient profile. Although angina was associated with a
poor prognosis, this was only true in patients with prior MI but not in
patients without prior MI. Patients with angina usually have relatively
infrequent episodes of ischaemia often occurring in response to exer-
cise or emotional stress, and in the absence of a suitable substrate
Hazard Rao P value
Age per year 100.0 <)40.1- 30.1( 40.1
Gender, reference: male 433.0)60.1- 58.0( 59.0
Smoking status, reference: never
. current 100.0 <)99.1- 15.1( 47.1
. former 1.29 (1.17 - 1.42)
Diabetes, reference: no 100.0 <)35.1- 82.1( 04.1
History of hypertension, reference: no 126.0)80.1- 88.0( 89.0
History of PCI, reference: no 100.0 <)39.0- 87.0( 58.0
History of CABG, reference: no 907.0)21.1- 29.0( 20.1
History of MI, reference: no 100.0 <)56.1- 73.1( 05.1
History of HF, reference: no 100.0 <)24.2- 78.1( 31.2
Asthma/COPD, reference: no 900.0)63.1- 40.1( 91.1
Peripheral artery disease, reference: no 100.0 <)54.1- 51.1( 92.1
Cerebrovascular disease, reference: no 635.0)02.1- 19.0( 50.1
Atrial ﬁbrillaon/ﬂuer, reference: no 100.0 <)28.1- 24.1( 16.1
History of stroke, reference: no 100.0 <)67.1- 02.1( 54.1
Angina at baseline, reference: no 100.0 <)54.1- 81.1( 03.1
BP <140/90mmHg at baseline, reference: no 320.0)99.0- 38.0( 09.0
Geographical area, ref. West/Central Europe
. Eastern Europe 1.09 (0.93 - 1.27)
. Middle East 1.21 (0.99 - 1.49)
< 0.001
. Asia 0.89 (0.78 - 1.02)
. Central/South America 1.61 (1.38 - 1.88)
. Commonwealth countries 1.16 (1.04 - 1.31)
Lower
event risk
Higher
event risk
0.5 1.0 1.5 2.0 2.5
Figure 1 Forest plot for multivariable analysis to determine the main predictors of cardiovascular death or myocardial infarction in the entire
CLARIFY population. BP, blood pressure; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; CV, cardiovascular;
HF, heart failure; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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unlikely to cause harm. A previous MI is a circumstance where such a
normally benign episode of ischaemia may lead to a devastating out-
come with a much higher risk to develop serious ventricular arrhyth-
mias or acute HF.
Moreover, the state of coronary arteries is an important determin-
ant of outcome in patients with angina. Given the expected higher
prevalence of vulnerable plaques in patients with previous MI, it is
expected that the latter will fare worst irrespective of the severity or
even extent of atheromatous disease. The implications of this finding
are clear: patients with prior MI and angina symptoms represent 14%
of the chronic coronary syndrome population and are at highest risk.
They deserve more intensive monitoring and management and par-
ticular attention should be devoted to implementing secondary pre-
vention strategies and ensuring targets are met.23–26 A clearer
understanding of which patient profiles have the worst outcomes is
necessary to focus follow-up efforts and appropriately target new
therapies that are either expensive or can have carry risks and side ef-
fect (e.g. rivaroxaban,20 PCSK9 inhibitors21, or canakinumab22). In
contrast, patients with angina but no prior MI may not deserve ag-
gressive non-invasive testing.
When attempting to improve patient care, RCTs and registries are
both useful. While RCTs are the gold-standard to evaluate new
therapies, they are often restricted to highly selected populations and
may not reflect daily practice.27 In contrast, registries are poorly
suited to determine treatment efficacy or safety but provide import-
ant data on large number of patients from routine clinical practice in
terms of describing patient characteristics, management and out-
comes and identifying gaps between evidence and practice.
Guidelines on secondary prevention of chronic patients are available,
but largely rely on relatively old data pertaining to trials done in MI
survivors.28,29 Large observational studies in patients with chronic
coronary syndrome are scarce, or are often focused on patients with
angina,30 or restricted to a single geographic area.31–33
Despite the size, scope, and quality of the CLARIFY registry, this
analysis has several limitations, some of which are inherent to obser-
vational studies. Outcomes were not adjudicated and, given the diffi-
culty in ascribing death to a specific cause in long-term outpatient
studies, the incidence of cardiovascular mortality, in contrast to total
mortality, should be taken with caution. Monitoring was limited each
year to a random selection of 1% of the centres. These results refer
only to enrolled patients and reflect the CLARIFY inclusion criteria.
They do not necessarily apply to all chronic coronary syndrome
patients encountered in daily practice. This study may not be
extrapolated to patients managed in the USA, as there were no
patients enrolled in this country due to lack of local sponsor. Despite
a broad geographic scope encompassing 45 countries, CLARIFY only
reflects countries and regions with high- or middle-income. The
results cannot be extrapolated to important and large areas, such as
most of Africa and regions in Asia where access to expensive medical
care is limited. Causes of two-thirds of cardiovascular death (non-
related to an MI or a stroke) were classified as other cardiovascular
death and consequently were assumed rather than proven
5         4         3         2         1         
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Take home ﬁgure Kaplan–Meier estimate curves for cardiovascular death or myocardial infarction according to angina status and history of
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MI, myocardial infarction.
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cardiovascular death, as is often the case in long-term outpatient
studies where many deaths can occur out of hospital and where
documentation is often limited or absent.
In conclusion, this international study provides helpful information
to characterize the spectrum of patients with chronic coronary syn-
drome and inform patient management and future studies in this
population, across various geographic regions. In this broad popula-
tion with chronic coronary syndrome, rates of major cardiovascular
events were lower than those observed in historical datasets, which
may reflect improved global medical care particularly the high rates
of use of evidence-based therapies. Although angina was associated
with a poor prognosis, this was only true in patients with prior MI.
Patients with both angina and prior MI are an easily identifiable high-
risk group which may deserve more intensive treatment.
Supplementary material
Supplementary material is available at European Heart Journal online.
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